The German scientist who is studying the emergence of extremely rare blood clots linked to the Covid-19 vaccine from AstraZeneca, said on Tuesday, according to what “Reuters” reported, that Johnson & Johnson agreed to work with him in the research.
Returning to the study of the causes of clots, Grenacher examines in his paper the possibility of an immune response against vaccines in a manner similar to the disorder of “immune thrombocytopenia caused by the use of heparin,” explaining that the body may respond to some Covid-19 vaccines in an opposite way.
The European Medicines Agency announced yesterday that it suspects that the vaccine may cause an unwanted immune response, but Sabine Strauss, head of the safety committee, said she had not yet identified specific risk factors yet. “It would be very useful to know in advance whether the cause was some kind of genetic disorder or something else in the blood vessels,” she told reporters.
However, Grincher does not believe such a possibility, based on his experiences with the heparin-induced immune thrombocytopenia disorder, which challenges efforts to determine why some people are at risk of the condition.
Not genetically predisposed
He said, “We have performed an analysis of the complete genetic sequence of 3000 of these patients, and we have not been able to find a genetic predisposition” to the disease.
However, in his recent paper, which has not yet been reviewed by independent scientists, he hinted at the possibility that the technology behind the “AstraZeneca” dose, some of its components and the strong immune response that stimulates it, contributed to a chain of events that may outweigh many of the mechanisms that usually It keeps the human immune system under control.
It is noteworthy that Grainacher’s team has worked since mid-March to analyze samples from people who had strokes after taking an injection, “AstraZeneca”.
In his study, he focused on the possibility of the body producing an immune response to some vaccines by activating the factors that cause the growth of platelets in the bodies of recipients of some vaccines, which may cause clots.
It is noteworthy that the European Medicines Agency stressed yesterday that the benefits of getting a dose of the “Johnson & Johnson” vaccine, as in the case of “AstraZeneca”, still outweigh the risks of thrombosis, a position that Grainacher also supports.